Clinical Trial Update: Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial update on SBR759 showing efficacy in lowering serum phosphate in chronic kidney disease patients on hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• SBR759

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy | Phase 2 | Status: COMPLETED